Picture: Immunovia AB

Immunovia with acting CEO

Immunovia AB announces that Philipp Mathieu has been appointed as acting CEO and President with immediate effect. The search for a permanent CEO continues, as previously communicated.

Philipp Mathieu has extensive experience as an adviser on corporate strategy, M&A and capital markets transactions to healthcare and life sciences companies, both in Europe and in the US. He has also held leadership positions in the financial sector and has extensive proficiency as an investor. The Board has entrusted him to rapidly advance the strategic priorities of the company, while it rolls out its IMMray™ PanCan-d test in the US.

“The appointment of Philipp as acting CEO ensures that we maintain our strategic momentum. I am pleased to welcome Philipp whose experience both in Europe and the US will be a valuable addition to the company. He possesses the qualifications and experience which Immunovia needs at present, and I look forward to working closely with him to realize the next phase of development of Immunovia”, says Carl Borrebaeck, Chairman of the Board of Directors at Immunovia.

Patrick Dahlen, President and CEO since November 2020, had informed the Board of Directors to step down, for personal reasons.